priors.science/reviews/atrial-fibrillation-stroke-prevention

Atrial Fibrillation Stroke Prevention

The current evidence on 21 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

21claims tracked

312primary papers reviewed

9 Aug 2026latest evidence review

Weeklyre-scored against new papers

5 Established · 8 Likely · 3 Uncertain · 5 Doubtful | four-reviewer panel · PICO Framework

ClaimStandingEvidence certaintyCorpus

Direct oral anticoagulants reduce stroke versus warfarin in atrial fibrillationAnticoagulationEstablished90%4

CHA2DS2-VASc predicts atrial fibrillation stroke riskRisk StratificationEstablished88%20

Ablation reduces atrial fibrillation recurrence versus antiarrhythmic drugsAblationEstablished87%20

Early oral anticoagulation after atrial fibrillation stroke is safeAnticoagulationEstablished87%14

Direct oral anticoagulants lower intracranial haemorrhage risk versus warfarin in atrial fibrillationAnticoagulationEstablished86%14

Early rhythm control reduces atrial fibrillation eventsRhythm VS RateLikely83%23

Apixaban reduces stroke in subclinical atrial fibrillationSubclinical AFLikely83%17

Ablation improves left ventricular function in heart failure with reduced ejection fractionAblationLikely81%20

Surgical left atrial appendage occlusion reduces strokeLaa OcclusionLikely80%17

Oral anticoagulation reduces stroke in atrial fibrillation with chronic kidney diseaseAnticoagulationLikely75%13

Direct oral anticoagulants safer than vitamin K antagonists in atrial fibrillation with chronic kidney diseaseAF CKDLikely70%10

Oral anticoagulation reduces stroke in atrial fibrillation with heart failure with reduced ejection fractionAF Heart FailureLikely70%14

Subclinical atrial fibrillation thromboembolic riskSubclinical AFLikely70%16

Rhythm control in atrial fibrillation with heart failure with preserved ejection fractionAF Heart FailureUncertain66%14

CHA2DS2-VA versus CHA2DS2-VASc for stroke predictionRisk StratificationUncertain55%14

Oral anticoagulation discontinuation after atrial fibrillation ablationAblationUncertain50%16

Female sex as a stroke risk modifier in atrial fibrillationRisk StratificationDoubtful48%20

Percutaneous left atrial appendage occlusion versus oral anticoagulation for strokeLaa OcclusionDoubtful45%17

Rhythm control benefit weaker in older atrial fibrillation patientsRhythm VS RateDoubtful45%19

Net oral anticoagulation benefit in subclinical atrial fibrillationSubclinical AFDoubtful42%17

Oral anticoagulation net benefit in atrial fibrillation on dialysisAF CKDDoubtful40%11

Track Atrial Fibrillation Stroke Prevention.

These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.

Track this topic →

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely70–84%Well supported, with some gaps or indirect evidence.

Uncertain50–69%Mixed or limited evidence. Genuinely open.

Doubtful30–49%Little support; the weight of evidence leans against it.

Refuted< 30%The evidence contradicts it — confidently false as stated.